Stifel Downgrades Apogee Therapeutics to Hold with Price Target of $135
Stifel downgraded Apogee Therapeutics (APGE) to Hold from Buy with a price target of $135, up from $133, after the company entered into an agreement to be acquired by AbbVie (ABBV) for $135.11 per share in cash. The firm considers this to be "a great outcome" for Apogee and its shareholders, the analyst tells investors.
